Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies
Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage...
Cell-therapy
Jiyuan Biotechnology’s Stem Cell Therapy for Type 2 Diabetes Gains NMPA Tacit Approval for Clinical Trials
BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the...
JW Therapeutics’ CAR-T Therapy Carteyva Secures NMPA Approval for Mantle Cell Lymphoma Indication
JW Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
Legend Biotech’s Carvykti Receives NMPA Approval for Relapsed/Refractory Multiple Myeloma After Multi-Center Phase II Study
Legend Biotech Corporation (NASDAQ: LEGN) has secured a significant milestone with the announcement of marketing...
CARsgen Completes Patient Enrollment for Phase II Trial of CT041 in Advanced Gastric Cancer
CARsgen Therapeutics Holdings Ltd (HKG: 2171), a leading China-based developer of chimeric antigen receptor (CAR)-T...
IASO Biotherapeutics’ CAR-T Therapy Fucaso Gets FDA Green Light for Lupus Treatment
IASO Biotherapeutics, a Chinese biotech firm, has received Investigational New Drug (IND) approval from the...
WuXi Biologics Partners with Medigene for TCR TCE Development in Refractory Tumors
WuXi Biologics (HKG: 2269), a leading Contract Research, Development and Manufacturing Organization (CRDMO) in China,...
Northeast Pharmaceutical to Acquire Majority Stake in Cell Therapy Specialist Dingcheng Taiyuan
Northeast Pharmaceutical Co., Ltd (SHE: 000597), a Chinese pharmaceutical company, has announced plans to acquire...
Huadong Medicine Secures Exclusive Rights to Immunochina’s CAR-T Therapy in China
China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has entered into a licensing agreement...
IASO Biotherapeutics’ CAR-T Therapy Fucaso Receives FDA IND Approval for Multiple Sclerosis
China-based IASO Biotherapeutics has announced that it has received Investigational New Drug (IND) approval from...
ST Phi Therapeutics’ Universal Cell Therapy for Solid Tumors Gets Green Light for Clinical Trial in China
ST Phi Therapeutics, a Hangzhou-based cell therapy specialist, has secured tacit approval from China’s National...
China’s NMPA Considers Breakthrough Designations for Xiangxue and Innostellar’s Therapies
Xiangxue Pharmaceutical Co., Ltd (SHE: 300147) and Innostellar Biotherapeutics Co., Ltd have both been noted...
Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) and Kite Pharma, a subsidiary...
Shanghai Medicilon and Jiangsu Hengrui Join Forces to Advance Pre-Clinical Drug Evaluation
Shanghai Medicilon Biomedical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...
Celling Biotechnology’s CEL001 Earns Tacit Approval for Clinical Trials in China
Celling Biotechnology Co., Ltd, a Guangzhou-based biopharmaceutical company, has announced that its pipeline candidate CEL001...
Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...
Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy Earns FDA Fast Track for Multiple Myeloma
Oricell Therapeutics Co., Ltd, a leading biopharmaceutical company based in China, has announced that it...
Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit
Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell...
GRIT Biotechnology and Quangang Pharmaceutical Co., Ltd Partner to Develop TIL and IL-2 Combination Therapy
GRIT Biotechnology, a leading cell therapy specialist based in China, has entered into a strategic...
Innovent Biologics and IASO Biotherapeutics Amend Partnership, Focusing on CAR-T Therapy Fucaso
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced a...